abrdn plc Has $7.88 Million Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

abrdn plc grew its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 31.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 306,723 shares of the company's stock after buying an additional 73,893 shares during the period. abrdn plc owned about 0.35% of IDEAYA Biosciences worth $7,883,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Covestor Ltd raised its position in shares of IDEAYA Biosciences by 23,050.0% during the 3rd quarter. Covestor Ltd now owns 926 shares of the company's stock worth $29,000 after purchasing an additional 922 shares during the period. Allworth Financial LP raised its position in shares of IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company's stock worth $29,000 after purchasing an additional 800 shares during the period. R Squared Ltd acquired a new stake in shares of IDEAYA Biosciences during the 4th quarter worth approximately $35,000. US Bancorp DE raised its position in shares of IDEAYA Biosciences by 67.2% during the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company's stock worth $54,000 after purchasing an additional 689 shares during the period. Finally, KBC Group NV raised its position in shares of IDEAYA Biosciences by 29.1% during the 3rd quarter. KBC Group NV now owns 2,274 shares of the company's stock worth $72,000 after purchasing an additional 513 shares during the period. Institutional investors own 98.29% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on IDYA. Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Oppenheimer restated an "outperform" rating and issued a $53.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. UBS Group assumed coverage on IDEAYA Biosciences in a research report on Thursday, October 24th. They set a "buy" rating and a $50.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Finally, Leerink Partners cut IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $41.00 to $27.00 in a research report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $53.67.

IDEAYA Biosciences Price Performance

Shares of IDYA traded up $0.57 during trading hours on Wednesday, hitting $21.95. 581,083 shares of the company were exchanged, compared to its average volume of 848,596. The company has a market capitalization of $1.90 billion, a PE ratio of -9.42 and a beta of 0.82. The firm has a fifty day simple moving average of $24.73 and a 200-day simple moving average of $30.24. IDEAYA Biosciences, Inc. has a one year low of $20.92 and a one year high of $47.74.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.